Magnesio para los calambres musculares esqueléticos
Información
- DOI:
- https://doi.org/10.1002/14651858.CD009402.pub2Copiar DOI
- Base de datos:
-
- Cochrane Database of Systematic Reviews
- Versión publicada:
-
- 12 septiembre 2012see what's new
- Tipo:
-
- Intervention
- Etapa:
-
- Review
- Grupo Editorial Cochrane:
-
Grupo Cochrane de Neuromuscular
- Copyright:
-
- Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cifras del artículo
Altmetric:
Citado por:
Autores
Contributions of authors
Protocol Stage: Dr Garrison drafted the protocol and the other authors commented and approved the final text.
Review Stage: Dr Garrison and Dr Sekhon selected studies for inclusion. Dr Garrison and Dr Allan extracted data. Drs Garrison, Allan and Musini rated studies for bias (Dr Garrison did not participate in the rating of his own trial). Dr Garrison performed all data analysis and wrote the draft manuscript. All authors commented on and approved the final text.
Sources of support
Internal sources
-
No sources of support supplied
External sources
-
Canadian Institutes of Health Research ‐ Doctoral Research Award in the Area of Research on Aging, Canada.
Trainee Stipend (Dr. Garrison)
Declarations of interest
Drs Garrison and Khan are co‐authors of a RCT which was included in this review. None of the co‐authors of this review have links, financial or otherwise, to any company or special interest group that is involved in the marketing of magnesium or other cramp related therapies.
Acknowledgements
The Cochrane Neuromuscular Disease Group editorial base is supported by the MRC Centre for Neuromuscular Disease, the Motor Neurone Disease Association and the Muscular Dystrophy Campaign. Penelope M. A. Brasher, PhD, provided statistical support for this review and Shannon Long, MLIS, assisted with literature retrieval.
Version history
| Published | Title | Stage | Authors | Version |
| 2020 Sep 21 | Magnesium for skeletal muscle cramps | Review | Scott R Garrison, Christina S Korownyk, Michael R Kolber, G Michael Allan, Vijaya M Musini, Ravneet K Sekhon, Nicolas Dugré | |
| 2012 Sep 12 | Magnesium for skeletal muscle cramps | Review | Scott R Garrison, G Michael Allan, Ravneet K Sekhon, Vijaya M Musini, Karim M Khan | |
| 2011 Nov 09 | Magnesium for skeletal muscle cramps | Protocol | Scott R Garrison, G Michael Allan, Ravneet K Sekhon, Vijaya M Musini, Karim M Khan | |
Differences between protocol and review
Searching other resources
We ultimately carried out three additional approaches to obtaining studies for our review that we had not pre‐identified in our study protocol. As a result we added a sentence to the end of the "Searching other resources" section of the protocol which states: "We also searched the International Clinical Trials Registry Platform (WHO‐ICTRP) in an attempt to uncover unpublished trials, searched ISI Web of Science for papers citing the studies included in this review, and contacted the FDA to ask if they had any related clinical trial information in their possession."
'Summary of findings' table addition
Under the heading 'Secondary outcomes' in the study protocol we had pre‐identified our plans for a 'Summary of findings table' with several elements. Since considerably more poolable data were available for the outcome "Number of cramps per week at four weeks" (i.e. there were four poolable studies, compared to just two for the other frequency estimates) we chose to add this outcome to the 'Summary of findings' table. We did this because we believed number of cramps per week at four weeks to be the most reliable measure of cramp frequency given the greater amount of available data.
Number of subjects reporting minor adverse events
Although we wished to determine the number of subjects reporting any minor adverse events this was not possible from the trial descriptions, which typically described the occurrence of adverse events but not the number of subjects with one or more adverse events (i.e. the same patient could contribute to the reporting of multiple adverse events). As a result, our description of minor adverse events was qualitative.
